GlaxoSmithKline has recently secured approval from the U.S. Food and Drug Administration for a new and improved shingles vaccine, Shingrix.
GSK's shot has fared significantly better than Merck’s Zostavax in clinical trials. According to Reuters, the vaccine is considered one of the more pivotal products in GSK's pipeline, with annual sales forecast to reach 1.03 billion pounds ($1.36 billion) by 2023.
The U.S. Centers for Disease Control and Prevention’s advisory committee on immunization practices will vote on a Shingrix use recommendation on Wednesday.
Also, GSK’s gene therapy Strimvelis for treating ADA-SCID (also known as “bubble boy” disease) won approval from Britain’s National Institute for Health and Care Excellence (NICE). .
Even though the therapy carries a price tag of nearly $698,000, infants with the condition need to be kept in isolation to avoid infections and the cost to the state health service can run into several millions of dollars.
Read the Reuters report